Clinical Trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-3
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Protocol Amendment History 4 changes
notable Trial sites expanded: 51 -> 69 locations 2026-07-07
notable Trial sites expanded: 37 -> 51 locations 2026-06-06
notable Trial sites expanded: 31 -> 37 locations 2026-05-09
notable Trial sites expanded: 23 -> 31 locations 2026-04-14
Trial Details
NCT Number NCT07266441
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 157 participants
Start Date 2026-02-08
Primary Completion 2027-06-14 (estimated)
Study Completion 2028-12-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06